Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models. (Record no. 2581)

MARC details
000 -LEADER
fixed length control field 02784nam a22003737a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 170823s20172017 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 2049-3614
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 28790138
245 ## - TITLE STATEMENT
Title Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models.
251 ## - Source
Source Endocrine Connections. , 2017 Aug 08
252 ## - Abbreviated Source
Abbreviated source Endocr. connect.. , 2017 Aug 08
252 ## - Abbreviated Source
Former abbreviated source Replace Dates
253 ## - Journal Name
Journal name Endocrine connections
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2017
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2018
266 ## - Date added to catalog
Date added to catalog 2017-08-23
520 ## - SUMMARY, ETC.
Abstract BACKGROUND: Amifostine is a potent scavenger of reactive oxygen species that is used for the salivary gland protection during therapy with radioactive iodine for thyroid cancer. There are no data on the potential effect of amifostine on thyroid cancer cells.
520 ## - SUMMARY, ETC.
Abstract CONCLUSIONS: Our data show that amifostine has no protective effect on thyroid cancer cells against DNA damaging agents in vitro and suggest that amifostine will not attenuate the efficacy of radioiodine treatment in patients with thyroid cancer.
520 ## - SUMMARY, ETC.
Abstract METHODS: We investigated the effects of the active form of amifostine (WR-1065) on the response of thyroid cancer cells to treatment with DNA damaging agents. WR-1065 was examined in human thyroid cancer cell lines (FTC133, TPC1, BCPAP and C643) and embryonic fibroblast cells NIH3T3. DNA damage was induced by exposure to H2O2 (0.1 mM), by treatment with the radiomimetic neocarzinostatin (NCS 250 ng/ml), and by gamma -radiation (6Gy). DNA damage, cell viability and apoptosis were examined.
520 ## - SUMMARY, ETC.
Abstract RESULTS: We demonstrated selective action of WR-1065 (0.1mM), which prevented oxidative stress induced DNA damage in fibroblasts, but did not protect thyroid cancer cells from DNA damage and apoptosis documented by caspase-3 and PARP cleavage after exposure to H2O2, NCS, and gamma-radiation. Prolonged exposure to WR-1065 (0.1 mM for 24 hours) was toxic for thyroid cancer cells; this treatment decreased the number of viable cells by 8% in C643 cells, 47% in TPC cells, 92% in BCPAP cells, and 82% in FTC 133 cells. The cytotoxic effects of WR-1065 were not associated with induction of apoptosis.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element PubMed-not-MEDLINE -- Not indexed
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Medicine/Endocrinology
656 ## - INDEX TERM--OCCUPATION
Department Medicine/Nuclear Medicine
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Burman, Kenneth D
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Van Nostrand, Douglas
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Wartofsky, Leonard
790 ## - Authors
All authors Burman K, Costello J, Jensen K, Klubo-Gwiezdzinska J, Patel A, Tkavc R, Van Nostrand D, Vasko V, Wartofsky L
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1530/EC-17-0138">https://dx.doi.org/10.1530/EC-17-0138</a>
Public note https://dx.doi.org/10.1530/EC-17-0138
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 08/23/2017   28790138 28790138 08/23/2017 08/23/2017 Journal Article

Powered by Koha